Strong sales of drugs for diabetes, cancer and animals helped the Indianapolis drugmaker overcome falling sales of older drugs for depression and osteoporosis, pushing up fourth-quarter sales and profit.
Indianapolis-based Eli Lilly and Co., which has promised to return to growth after a half-decade of falling revenue, indicated that 2016 earnings might be below analysts’ estimates.
The companies will work on coupling therapies from Lilly with technology from Halozyme Therapeutics that helps the body disperse and spread medicine.
The FDA said Wednesday it approved Basaglar based on data showing it is safe and effective and works similarly to Lantus, the world’s top-selling insulin.
Until impending patent expirations spurred the company to forgo a dividend increase in 2010, the company had announced dividend increases for 42 consecutive years.
Eli Lilly and Co. is in the process of separating the manufacturing of its animal health drugs from the facilities used to make its traditional pharmaceuticals, a move that potentially could make it easier to spin off the division one day.
Eli Lilly said Friday that it decided to stop developing the insulin peglispro after learning that it would take more time and cost more than expected to understand a significant side effect.
Dozens of companies across central Indiana are using programs aimed at middle- and high-school students to develop a pool of talented kids who are interested in science, technology, engineering and math to fill the growing number of jobs for which such skills are necessary.
In a vote Tuesday, the American Medical Association called for an end to television commercials and magazine spreads that are used to pitch prescription drugs directly to consumers.
The number of prescriptions for Addyi, the women’s libido-boosting pill, in its first few weeks? 227.
Indianapolis-based Eli Lilly and Co. and other U.S. drugmakers are being investigated by federal prosecutors over their drug-pricing practices related to Medicare and Medicaid, according to newspaper reports.
The 130,000-square-foot building will be designed to encourage collaboration among scientists across different disciplines, which the company said is crucial to fostering innovation.
Jeff Simmons is on a counteroffensive as, increasingly, the drugs that Elanco makes—including antibiotics and productivity enhancers—have come under attack by food activists.
Eli Lilly and Co. beat Wall Street’s expectations with its third-quarter profit, prompting the drugmaker to raise its full-year forecast by as much as 20 cents per share.
For the $300 billion pharmaceutical industry, the rapid growth of illegal underground marketplaces is a serious threat to profits and reputations.
AstraZeneca Plc didn’t receive U.S. approval for a new diabetes treatment that combines two of its existing drugs. The combination would have competed with Glyxambi from Lilly.
Eli Lilly shares plunged nearly 10 percent Monday morning after it said it would stop development of evacetrapib, an experimental cholesterol drug with blockbuster potential.
Suzhou, China-based Innovent could receive payments totaling more than $1 billion if the cancer products it develops with Lilly reach certain milestones.
The drugmaker is trying to beef up its work on using the immune system to fight cancer. Indianapolis will remain Lilly’s main hub for research and development.
Puerto Rico officials are looking to replace an expiring tax with a new levy to draw much-needed revenue from the world’s best-selling medications while seeking to avoid driving U.S. manufacturers such as Eli Lilly and Co. from the commonwealth.
